Supplementary Table 2. Summary of studies included in the pooled safety analysis of the entire secukinumab treatment period (from commencement date up to the cut-off date of June 25, 2017)

Study name	Study identifier	Number of patients included	Comparator	Dose of secukinumab
Psoriasis studies				
CLEAR (2317)	NCT02074982	335	Ustekinumab, placebo	300 mg qw/q4w SC
GESTURE (2312)	NCT01806597	199	Placebo	300, 150 mg qw/q4w SC
ERASURE (2302)	NCT01365455	702	Placebo	300, 150 mg qw/q4w SC
JUNCTURE (2309)	NCT01636687	177	Placebo	300, 150 mg qw/q4w SC
FIXTURE (2303)	NCT01358578	936	Etanercept and Placebo	300, 150 mg qw/q4w SC
SCULPTURE (2304)	NCT01406938	966	N/A	300, 150 mg qw/q4w SC, RAN
FEATURE (2308)	NCT01555125	174	Placebo	300, 150 mg qw/q4w SC
TRANSFIGURE (2313)	NCT01807520	190	Placebo	300, 150 mg qw/q4w SC
2PRECISE (3301)	NCT02008890	214	Placebo	300, 150 mg qw/q4w SC
CARIMA (ADE02)	NCT02559622	150	Placebo	300, 150 mg qw/q4w SC
PSORITUS (ADE03)	NCT02362789	130	Placebo	300 mg qw SC
GAIN (ADE04)	NCT02474069	772	N/A	300 mg q4w SC

PRIME (ADE06)	NCT02474082	105	Fumaric acid esters	300 mg qw/q4w SC
JP01	NCT02547714	34	N/a	300 mg q4w SC
SCALP (AUS01)	NCT02267135	97	Placebo	300 mg q4w SC
Psoriatic arthritis studies				
FUTURE 1 (2306)	NCT01392326	587	Placebo	10 mg/kg IV → 150, 75 mg q4w SC
FUTURE 2 (2312)	NCT01752634	387	Placebo	300, 150, 75 mg qw/q4w SC
FUTURE 3 (2318)	NCT01989468	406	Placebo	300, 150 mg qw/q4w SC
Ankylosing spondylitis studies				
MEASURE 1 (2305)	NCT01358175	360	Placebo	10 mg/kg IV → 150, 75 mg q4w SC
MEASURE 2 (2310)	NCT01649375	211	Placebo	150, 75 mg qw/q4w SC
MEASURE 3 (2314)	NCT02008916	223	Placebo	10 mg/kg IV → 300, 150 mg q4w SC

IV, intravenous; Qw, once a week; Q4w, every 4 weeks; SC, subcutaneous; RAN, retreatment as needed